

Cover Story
News Analysis
By Jacquelyn Cobb and Sara Willa Ernst
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Sponsored
By John’s Hopkins Kimmel Cancer Center Communications
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for March
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pam Bondi diagnosed with thyroid cancer
- As FDA’s wheels almost entirely come off, NCI remains sturdy—a cancer moonshot may even be on the horizon
- Charles Rudin named cancer center director at MSK
- UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
















